Newsroom

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-3 Class F 144A XS2909753365 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84353568% Margin: 4.75% Total Rate: 8.59353568% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly...

NEW YORK--(BUSINESS WIRE)--Aspen Power, a leading distributed generation platform backed by Carlyle and dedicated to building the clean energy future, today announced the successful closing of a $200 million capital raise provided by Deutsche Bank. The new capital commitment will bolster Aspen Power’s financial capacity and support growth initiatives across development, vendor engagement, and project deployment as it scales its platform nationwide. The financing positions Aspen Power to respond...

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco. Throughout the conference, Turn Therapeutics will participate in investor and partner meetings to...

PHILADELPHIA & SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, today announced a clinical collaboration to conduct a Phase 1 trial in China, planned to begin in 2026. The trial will evaluate DISP-11, an investigational therapy leveraging Disp...

SAN DIEGO--(BUSINESS WIRE)--Mitek Systems, Inc. (NASDAQ: MITK), a global leader in digital identity verification and fraud prevention, has been recognized for its strong performance in a recent independent evaluation by Datos Insights, a respected financial services research and advisory firm. In the Datos Insights Matrix for Document Identity Verification, Mitek was positioned as a Market Leader, demonstrating strong performance across both product capabilities and execution, the core dimensio...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term gro...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 09.01.2026 FVD. IE00BKVKW020 250,002.00 USD 7,101,771.18 28.407  ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2025 of at least 17% year over year. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “We enter 2026 with strong momentum and...

SAN FRANCISCO--(BUSINESS WIRE)--Junevity Announces First Peer-reviewed Research Showing Single-Target Repression Can Reprogram Cellular Aging...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics, Inc. (“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ETX101 for the treatment of SCN1A+ Dravet syndrome. This designation is in addition to Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease D...